DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
- Conditions
- Lymphoma
- Interventions
- Other: laboratory biomarker analysis
- Registration Number
- NCT01057459
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Brief Summary
This research trial studies deoxyribonucleic acid (DNA) analysis in predicting response to antibody therapy in patients with follicular lymphoma treated on clinical trials Cancer and Leukemia Group B (CALGB)-50402 or CALGB-50701. Studying samples of blood from patients with follicular lymphoma in the laboratory may help doctors predict how well patients will respond to treatment.
- Detailed Description
PRIMARY OBJECTIVES:
l. To test the hypothesis that killer immunoglobulin-like receptor (KIR) and human leukocyte antigen (HLA) genotypes predict overall response (partial response \[PR\], complete response\[CR\], and unconfirmed complete response \[CRu\]) within 12 months to rituximab-containing monoclonal antibody combinations in follicular lymphoma patients treated on CALGB protocols 50402 and 50701.
SECONDARY OBJECTIVES:
I. To test the hypothesis that KIR and HLA genotypes are associated with survival outcomes (progression-free survival \[PFS\] and overall survival \[OS\]) in follicular lymphoma patients treated with rituximab-containing monoclonal antibody combinations on CALGB protocols 50402 and 50701.
OUTLINE:
Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 78
- Untreated follicular lymphoma
- Has received rituximab-containing monoclonal antibody therapy on CALGB-50402 or CALGB-50701
- Patients have previously provided informed consent allowing correlative studies on genomic DNA
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Ancillary-Correlative (biomarkers and treatment outcomes) laboratory biomarker analysis Genomic DNA is extracted from previously collected blood samples for KIR and HLA genotyping and polymorphism analysis.
- Primary Outcome Measures
Name Time Method overall response Baseline
- Secondary Outcome Measures
Name Time Method Progression-free survival Baseline Overall survival Baseline
Trial Locations
- Locations (1)
Memorial Sloan-Kettering Cancer Center
🇺🇸New York, New York, United States